Clinical Investigation of Daydrop® Triple Action for the Symptomatic Treatment of Allergic Conjunctivitis.
The study is designed to evaluate the safety and efficacy of Daydrop® Triple Action for the symptomatic treatment of seasonal or perennial allergic conjunctivitis. It is a prospective, post-market clinical investigation using a quasi-experimental before-and-after design with intra-subject control. Daydrop® Triple Action is an ophthalmic solution containing ectoine, hyaluronic acid, and carboxymethylcellulose, developed to hydrate, lubricate, and protect the ocular surface, helping to relieve symptoms such as itching, redness, tearing, and foreign body sensation. The study will enroll 49 adult patients with active allergic conjunctivitis and will follow them for 14 days, with assessments at baseline, 24 hours, 7 days, and 14 days. Participants will use the product once or twice daily, according to the investigator's judgment. The primary efficacy endpoint is the reduction of ocular itching, while the primary safety endpoint is the incidence of serious adverse events. Secondary assessments include changes in ocular redness, overall ocular symptoms, clinical signs of allergic conjunctivitis, tear film stability (TBUT), patient satisfaction, and global improvement evaluations by both the investigator and the patient. Overall, the study aims to generate clinical evidence demonstrating that Daydrop® Triple Action is a safe and effective non-pharmacological option for improving the signs and symptoms associated with allergic conjunctivitis.
• Adults aged 18 years or older
• Active episode of allergic conjunctivitis prior to study initiation, assessed and confirmed by the specialist using a slit-lamp examination.
• Score of ≥ 2 points on either the Ora Calibra Ocular Itching Score or the Ocular Redness Score, as assessed by the participant and the investigator, respectively.
• Ability to self-administer the study product.
• Ability to understand the Patient Information Sheet and provide written informed consent.